Mitochondrial injury in steatohepatitis

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 11, 2004, Pages 1095-1105

  Pessayre, Dominique ^a   Fromenty, Bernard ^a   Mansouri, Abdellah ^a  

^a INSERM   (France)

Author keywords

Apoptosis; Fas; Lipid peroxidation; Mitochondria; Reactive oxygen species; Steatohepatitis; Steatosis; TNF

Indexed keywords

CARDIOLIPIN; CYTOCHROME C; FAS ANTIGEN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CYTOKINE RELEASE; DIET; DISEASE PREDISPOSITION; DNA DAMAGE; ENZYME RELEASE; EXERCISE; FATTY ACID OXIDATION; FATTY LIVER; FIBROGENESIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER INJURY; LIVER MITOCHONDRION; MALLORY BODY; MITOCHONDRIAL MEMBRANE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

ADIPOCYTES; APOPTOSIS; FATTY LIVER; HEPATITIS; HUMANS; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS; MITOCHONDRIA; MUSCLES; REACTIVE OXYGEN SPECIES;

EID: 8444226753     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200411000-00003     Document Type: Review

References (87)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
2. Clark JM, Brancati L, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122:1649-1657.
3. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21:57-69.
4. Pessayre D, Mansouri A, Fromenty B. Mitochondrial dysfunction in steatohepatitis. Am J Physiol (Gastrointest Liver Physiol) 2002; 282:G193-G199.
5. Pessayre D. Mitochondrial injury in steatohepatitis. In: Suchy FJ, Fitz JG, Maher JJ (course directors). Mechanisms of Acute and Chronic Liver Diseases: Implications for Diagnosis, Pathogenesis and Treatment. (American Association for the Study of Liver Diseases Postgraduate Course 2002) 2002, pp. 97-103.
6. Fromenty B, Pessayre D. Mitochondrial injury and NASH. In: Farrell G, Jacob J, Hall P, McCullough A (editors). Non-alcoholic Steatohepatitis. Oxford, UK: Blackwell Publishing; (in press).
7. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30:121-138.
8. Shepherd PR, Kahn BB. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341:248-257.
9. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420:353-356.
10. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance. Hepatology 2002; 35:373-379.
11. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37:1202-1219.
12. Valet P, Tavernier G, Castan-Laurell I, Sébastien J, Saulnier-Blache JS, Langin D. Understanding adipose tissue development from transgenic animal models. J Lipid Res 2002; 43:835-860.
13. Gorden ES. Non-esterified fatty acids in blood of obese and lean subjects. Am J Clin Nutr 1960; 8:740-747.
14. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, et al. Role of stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002; 297:240-243.
15. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, et al. Liver specific disruption of PPAR-γ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 2003; 111: 737-747.
16. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers of two mouse models of diabetes mellitus. J Biol Chem 1999; 274:30028-30032.
17. Brady LJ, Brady PS, Romsos DR, Hoppel CL. Elevated hepatic mitochondrial and peroxisomal oxidative capacities in fed and starved adult obese (ob/ob) mice. Biochem J 1985; 231:439-444.
18. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37:343-350.
19. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120:1183-1192.
20. Chalasani N, Gorki JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 544-550.
21. Miele L, Grieco A, Armuzzi A, Candelli M, Zocco MA, Forgione A, et al. Nonalcoholic-steatohepatitis (NASH) and hepatic mitochondrial beta-oxidation. J Hepatol 2003; 38 (suppl 2):197A.
22. Cook GA, Gamble MS. Regulation of carnitine palmitoyltransferase by insulin results in decreased activity and decreased apparent Ki values for malonyl-CoA. J Biol Chem 1987; 262:2050-2055.
23. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, Feingold KR. Dp-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ- responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000; 41:4021-4031.
24. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest 1999; 103:1489-1498.
25. Nakatani T, Tsuboyama-Kasaoka N, Takahashi M, Miura S, Ezaki O. Mechanism for peroxisome proliferator-activated receptor-α activator-induced up-regulation of UCP-2 mRNA in rodent hepatocytes. J Biol Chem 2002; 277:9562-9569.
26. Collins JC, Scheinberg IH, Giblin DR, Sternlieb I. Hepatic peroxisomal abnormalities in abetalipoproteinemia. Gastroenterology 1989; 97: 766-770.
27. De Craemer D, Pauwels M, Van den Branden C. Alterations of peroxlsomes in steatosis of the human liver: a quantitative study. Hepatology 1995; 22:744-752.
28. Tran K, Thorne-Tjomsland G, DeLong CJ, Cui Z, Shan J, Burton L, et al. Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH777 cells. J Biol Chem 2002; 277:31187-31200.
29. Bartels ED, Lauritsen M, Nielsen LB. Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 2002; 51:1233-1239.
30. Austin MA, King MC, Vranizan JM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:649-651.
31. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Transac 2003; 31: 1066-1069.
32. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898-904.
33. Sparks JD, Sparks CE. Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effects on hepatic apo B secretion. Biochem Biophys Res Commun 1994; 205:417-422.
34. Levy E, Sinnett D, Thibault L, Nguyen TD, Delvin E, Menard D. Insulin modulation of newly synthesized apolipoproteins B-100 and E in human fetal intestine: gene expression and mRNA editing are not involved. FEBS Lett 1996; 393:253-258.
35. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37:909-916.
36. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 1998; 27:128-133.
37. Fiorini RN, Shafizadeh SF, Chavin KD. Primary non-function in steatotic livers is due to differential Toll-like expression and endotoxin sensitivity. Hepatology 2002; 36:198A.
38. Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, Sato N. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-α production. Gastroenterology 2002; 123:291-300.
39. Lettéron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24:200-208.
40. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2001; 105:1067-1075.
41. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95:2111-2119.
42. Crespo J, Cayon A, Fernadez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor α and TNF-receptors p55 and p75 in nonalcoholic steatohepatitis patients. Hepatology 2001; 34:1158-1163.
43. 13C- methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis. Med Sci Monit 2003; 9:CR6-11.
44. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. A pilot study. JAMA 1999; 282:1659-1664.
45. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD Jr. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J Hepatol 1999; 31:430-434.
46. Haque M, Mirshahi F, Campbell-Sargent C, Sterling RK, Luketic VA, Shiffman VA, et al. Nonalcoholic steatohepatitis (NASH) is associated with hepatocyte mitochondrial DNA depletion. Hepatology 2002; 36:403A.
47. Hruszkewycz AM. Evidence for mitochondrial DNA damage by lipid peroxidation. Biochem Biophys Res Commun 1988; 153:191-197.
48. Hruszkewycz AM, Bergtold DS. The 8-hydroxyguanine content of isolated mitochondria increases with lipid peroxidation. Mutat Res 1990; 244:123-128.
49. Mansouri A, Gaou I, de Kerguenec C, Amsellem S, Haouzi D, Berson A, et al. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroentemlogy 1999; 117:181-190.
50. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 2002; 123:1278-1290.
51. Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, Mato JM, Corrales FJ. Functional proteomics of nonalcoholic sleatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA 2003; 100:3065-3070.
52. Pérez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38:999-1007.
53. Chen J, Schenker S, Frosto TA, Henderson GI. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme catalytic site. Biochem Biophys Acta 1998; 1380:336-344.
54. Chen J, Petersen DR, Schenker S, Henderson GI. Formation of malondialdehyde adducts in livers of rats exposed to ethanol: role of ethanolmediated inhibition of cytochrome c oxidase. Alcohol Clin Exp Res 2000; 24:544-552.
55. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria. Central role of complex III. J Biol Chem 2003; 38:36027-36031.
56. Yamagishi S, Edelstein D, Du X, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276:25096-25100.
57. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 2002; 277:44784-44790.
58. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000; 97:12222-12226.
59. + oxidation-reduction state. Biochem J 2002; 368:545-553.
60. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378:259-268.
61. 2 generation in liver mitochondria. Carcinogenesis 2000; 21: 983-988.
62. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21:89-104.
63. Rao MS, Papreddy K, Musunuri S, Okonkwo A. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats. In Vivo 2002; 16:145-152.
64. Robin MA, Anandatheerthavarada HK, Fang JK, Cudic M, Otvos L, Avadhani NG. Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific transfer proteins for activity. J Biol Chem 2001; 276:24680-24689.
65. Robin MA, Anandatheerthavarada HK, Biswas G, Sepuri NB, Gordon DM, Pain D, Avadhani NG. Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J Biol Chem 2002; 277: 40583-40593.
66. Raza H, Prabu SK, Robin MA, Avadhani NG. Elevated mitochondrial cytochrome P450 2E1 and glutathione S-transferase A4-4 in streptozotocin-induced diabetic rats: tissue specific variations and roles in oxidative stress. Diabetes 2004, 53:185-194.
67. Strauss RS. Comparison of serum concentrations of α-tocopherol and β-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). J Pediatr 1999; 134:160-165.
68. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136:734-738.
69. Trejo-Skalli AV, Velasco PT, Murthy SNP, Lorand L, Goldman RD. Association of a transglutaminase-related antigen with intermediate filaments. Proc Natl Acad Sci USA 1995; 92:8940-8944.
70. Pessayre D, Feldmann G, Haouzi D, Fau D, Moreau A, Neuman M. Hepatocyte apoptosis triggered by natural substances (cytokines, other endogenous substances and foreign toxins). In: Cameron RG, Feuer G (editors). Apoptosis and its Modulation by Drugs. (Handbook of Experimental Pharmacology, vol. 142.) Heidelberg: Springer Verlag; 2000, pp. 59-108.
71. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart U, Lindor KD, Gores GJ. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125:437-443.
72. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003; 39:978-983.
73. Nechushtan A, Smith CL, Lamendorf I, Yoon SH, Youle RJ. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 2001; 153:1265-1276.
74. Kirkland RA, Windelborn JA, Kasprzak JM, Franklin JL. A Bax-induced prooxidant state is critical for cytochrome C release during programmed neuronal death. J Neuroscience 2002; 22:6840-6490.
75. Feldmann G, Haouzi D, Moreau A, Durand-Schneider AM, Bringuier A, Berson A, et al. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. Hepatology 2000; 31:674-683.
76. Leist M, Single B, Castoldi AF, Kühnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185:1481-1486.
77. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101:890-898.
78. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83:655-663.
79. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, et al. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 1997; 11:851-857.
80. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen a1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 1993; 194:1044-1050.
81. Phung N, Farrell G, Robertson G, George J. Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology 2001; 34:361A.
82. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2001; 15:1667-1672.
83. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395:763-770.
84. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37:206-213.
85. Tang M, Potter JJ, Mezey E. Leptin enhances the effect of transforming growth factor beta in increasing type I collagen formation. Biochem Biophys Res Commun 2002; 297:906-911.
86. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122:1399-1340.
87. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35:762-771.